Kerry Blanchard (Everest)

Eli Lil­ly vet Ker­ry Blan­chard takes the helm at one of Chi­na's top deal­mak­ers, steer­ing to­ward first ap­provals

As Big Phar­ma op­er­a­tions in Chi­na con­tin­ue to bleed tal­ent to lo­cal biotech star­tups, an Eli Lil­ly vet is tak­ing on his first CEO role at one of the com­pa­nies hon­ing the mod­el of in-li­cens­ing late-stage West­ern drugs and tai­lor-mak­ing de­vel­op­ment pro­grams for the Chi­nese mar­ket.

Ever­est Med­i­cines has kept a rel­a­tive­ly low pro­file, but in its two-plus years of ex­is­tence it’s earned a spot as one of the top deal­mak­ers, mak­ing a splash last April by pay­ing a record $60 mil­lion up­front for Im­munomedics’ breast can­cer drug. Ker­ry Blan­chard is now tasked with steer­ing its eight as­sets to Chi­na ap­provals, with four reg­is­tra­tion tri­als un­der­way and two more planned lat­er this year.

“I have been aware of Ever­est Med­i­cine since its in­cep­tion in 2017,” Blan­chard told End­points News. “I was at­tract­ed by their con­cept of fo­cus­ing on tru­ly in­no­v­a­tive med­i­cines that are glob­al first in class or best in class as­sets. I be­lieve the time for first in class or best in class in on­ly Chi­na is rapid­ly com­ing to an end. Ever­est’s mod­el is a mod­el for the fu­ture; for the new era of in­no­va­tion in Chi­na.”

The drug can­di­dates span on­col­o­gy, im­munol­o­gy, car­dio-re­nal dis­ease and in­fec­tious dis­ease.

Ever­est is han­dling tri­als for er­ava­cy­cline (an­tibi­ot­ic from Tetraphase) in com­pli­cat­ed in­tra-ab­dom­i­nal in­fec­tion and etrasi­mod (S1P re­cep­tor mod­u­la­tor from Are­na) in ul­cer­a­tive col­i­tis on its own, Blan­chard said.

Ian Woo

Mean­while, the com­pa­ny will al­so par­tic­i­pate in glob­al tri­als — where Chi­na typ­i­cal­ly con­tributes 15%-20% of pa­tients — in the two oth­er pro­grams: VN­RX-5133 (an­tibi­ot­ic from Ve­na­toRX) in com­pli­cat­ed uri­nary tract in­fec­tions and ra­linepag (from Are­na) in pul­monary ar­te­r­i­al hy­per­ten­sion.

Sub­mit­ting over­seas da­ta for a Chi­na ap­proval, once a for­eign idea, is now com­mon prac­tice at the re­formed Na­tion­al Med­ical Prod­ucts Ad­min­is­tra­tion.

“If we can, we pre­fer to join glob­al reg­is­tra­tion tri­als, but in some in­stances based on tim­ing or the ge­o­graph­ic dif­fer­ence we will per­form lo­cal or re­gion­al reg­is­tra­tion tri­als,” Blan­chard said.

One NDA — though they didn’t spec­i­fy which one — is al­so in the road map for 2020.

The CBC Group — the pow­er­house pri­vate eq­ui­ty play­er for­mer­ly known as C-Bridge Cap­i­tal — put the com­pa­ny to­geth­er. Blan­chard joined CBC group a few months ago as an op­er­at­ing part­ner af­ter a brief stint at In­novent help­ing push their PD-1 sin­til­imab over the fin­ish line. And be­fore that, he spent eight years lead­ing Chi­na drug de­vel­op­ment for Lil­ly (which part­nered with In­novent on sin­til­imab) as part of a 17-year ca­reer at the phar­ma gi­ant.

Blan­chard, who takes over from CBC man­ag­ing di­rec­tor Sean Cao, said his pri­or­i­ties al­so in­clude grow­ing the team from 100 to 200.

“Com­pe­ti­tion for tal­ent is al­ways a chal­lenge, and es­pe­cial­ly so in Chi­na,” he said. “The mar­ket is very hot and tal­ent­ed peo­ple have many op­tions.”

Then there’s the chal­lenge of get­ting Ever­est ready for com­mer­cial­iza­tion, where Wende Chan — who re­cent­ly jumped from Roche to be­come Ever­est’s chief com­mer­cial of­fi­cer — will play a ma­jor role.

Amid a new fo­cus on dis­cov­er­ing tru­ly made-in-Chi­na med­i­cines, Blan­chard hint­ed that he will ex­plore strate­gic op­por­tu­ni­ties out­side the kind of late-stage re­gion­al li­cens­ing they’re most fa­mil­iar with.

“In the near fu­ture we ex­pect our BD ac­tiv­i­ties to ex­pand to in­clude more ear­li­er-stage as­sets, where we can lever­age Chi­na’s vast clin­i­cal re­sources,” Ian Woo, pres­i­dent, and CFO added. “Longer term, we plan to cre­ate sus­tain­abil­i­ty by build­ing out dis­cov­ery ca­pa­bil­i­ties.”

Tesla and SpaceX founder Elon Musk gestures to the audience after being recognized by President Trump following the successful launch of a Falcon 9 rocket at the Kennedy Space Center. (via Getty Images)

Tes­la chief Elon Musk teams up with Covid-19 play­er Cure­Vac to build 'R­NA mi­cro­fac­to­ries'

Elon Musk has joined the global tech crusade now underway to revolutionize vaccine manufacturing — now aimed at delivering billions of doses of a new mRNA vaccine to fight Covid-19. And he’s cutting right to the front.

In a late-night tweet Wednesday, the Tesla chief announced:

Tesla, as a side project, is building RNA microfactories for CureVac & possibly others.

That’s not a lot to go on. But the tweet comes a year after Tesla’s German division in Grohmann and CureVac filed a patent on a “bioreactor for RNA in vitro transcription, a method for RNA in vitro transcription, a module for transcribing DNA into RNA and an automated apparatus for RNA manufacturing.” CureVac, in the meantime, has discussed a variety of plans to build microfactories that can speed up the whole process for a global supply chain.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 84,700+ biopharma pros reading Endpoints daily — and it's free.

George Yancopoulos (Regeneron)

UP­DAT­ED: Re­gen­eron co-founder George Yan­copou­los of­fers a com­bat­ive de­fense of the po­lice at a high school com­mence­ment. It didn’t go well

Typically, the commencement speech at Yorktown Central School District in Westchester — like most high schools — is an opportunity to encourage students to face the future with confidence and hope. Regeneron president and co-founder George Yancopoulos, though, went a different route.

In a fiery speech, the outspoken billionaire defended the police against the “prejudice and bias against law enforcement” that has erupted around the country in street protests from coast to coast. And for many who attended the commencement, Yancopoulos struck the wrong note at the wrong time, especially when he combatively challenged someone for interrupting his speech with a honk for “another act of cowardness.”

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 84,700+ biopharma pros reading Endpoints daily — and it's free.

Elias Zerhouni (Photo by Vincent Isore/IP3/Getty Images)

Elias Zer­houni dis­cuss­es ‘am­a­teur hour’ in DC, the de­struc­tion of in­fec­tious dis­ease R&D and how we need to prep for the next time

Elias Zerhouni favors blunt talk, and in a recent discussion with NPR, the ex-Sanofi R&D and ex-NIH chief had some tough points to make regarding the pandemic response.

Rather than interpret them, I thought it would be best to provide snippets straight from the interview.

On the Trump administration response:

It was basically amateur hour. There is no central concept of operations for preparedness, for pandemics, period. This administration doesn’t want to or has no concept of what it takes to protect the American people and the world because it is codependent. You can’t close your borders and say, “OK, we’re going to be safe.” You’re not going to be able to do that in this world. So it’s a lack of vision, basically just a lack of understanding, of what it takes to protect the American people.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 84,700+ biopharma pros reading Endpoints daily — and it's free.

Look­ing for 'ex­ter­nal in­no­va­tion,' Boehringer In­gel­heim re­serves $500M+ for new Shang­hai hub

Now that Boehringer Ingelheim’s bet on contract manufacturing in China has paid off, the German drugmaker is anteing up more to get into the research game.

Boehringer has set aside $507.9 million (€451 million) for a new External Innovation Hub to be built in Shanghai over five years. The site will become one of its “strategic pillars” as the team strives to get 71 approvals — either for new products or indications — by 2030, said Felix Gutsche, president and CEO of Boehringer Ingelheim China.

Sec­ond death trig­gers hold on Astel­las' $3B gene ther­a­py biotech's lead pro­gram, rais­ing fresh con­cerns about AAV

Seven months after Astellas shelled out $3 billion to acquire the gene therapy player Audentes, the biotech company’s lead program has been put on hold following the death of 2 patients taking a high dose of their treatment. And there was another serious adverse event recorded in the study as well, with a total of 3 “older” patients in the study affected.

The incidents are derailing plans to file for a near-term approval, which had been expected right about now.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 84,700+ biopharma pros reading Endpoints daily — and it's free.

Vas Narasimhan, Novartis CEO (Patrick Straub/​EPA-EFE/​Shutterstock)

No­var­tis pays $678M for kick­back scheme as Vas Narasimhan tries to dis­tance phar­ma gi­ant from shady be­hav­ior

Novartis has reached another large settlement to resolve misconduct allegations, agreeing to pay more than $678 million to settle claims that it had spent hundreds of millions of dollars on lavish dinners, so-called speaking fees and expensive alcohol “that were nothing more than bribes” to get doctors to prescribe Novartis medications.

The top-shelf alcohol and lavish meals included a $3,250 per person night at Nobu in Dallas, a $672-per person dinner at Washington DC’s Smith & Wollensky and a $314 per person meal at Sushi Roku in Pasadena, according to the Justice Department complaint. There were at least 7 trips to Hooters and fishing trips in Alaska and off the Florida coast. Each of these events were supposed to be “speaker programs” where doctors educated other doctors on a drug, but the DOJ alleged many were “bogus” wine-and-dine events where the drug was barely mentioned, if at all.  (“Nobody presented slides on the fishing trips,” the complaint says.)

No­vavax snags Ben Machielse for CMC and pro­motes a trio of staffers; Mar­ty Du­vall lands an­oth­er CEO post at On­copep­tides

Novavax has been making waves recently by securing a $384 million commitment from CEPI to cover R&D and manufacturing for its Covid-19 vaccine while also spending $167 million on a 150,000 square-foot facility. The Maryland biotech continues to shore up its leadership team as well, bringing in Ben Machielse as their EVP of CMC just a couple weeks after nabbing AstraZeneca vet Filip Dubrovsky as their new CMO. Machielse was president and CEO of Vtesse from 2014-17, and before that, he also spent more than 11 years at MedImmune and was EVP of operations for the back half of his tenure.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 84,700+ biopharma pros reading Endpoints daily — and it's free.

Dan Gold, MEI Pharma CEO

De­vel­op­ment part­ners at MEI, Helsinn dump a high-risk PhI­II AML study af­ter con­clud­ing it would fail sur­vival goal

Four years after Switzerland’s Helsinn put $25 million of cash on the table for an upfront and near-term milestone to take MEI Pharma’s drug pracinostat into a long-running Phase III trial for acute myeloid leukemia, the partners are walking away from a clinical pileup.

The drug — an HDAC inhibitor — failed to pass muster during a futility analysis, as researchers concluded that pracinostat combined with azacitidine wasn’t going to outperform the control group in the pivotal.

No­var­tis los­es biosim­i­lar ap­peal as court up­holds a 31-year mo­nop­oly by Am­gen's En­brel

A new court ruling has strengthened Amgen’s grip on the IP estate around Enbrel, keeping biosimilars of the autoimmune and inflammatory drug at bay until 2029.

Novartis, the patent challenger, isn’t throwing in the towel yet. In a statement noting the failed appeal, its generics division Sandoz noted its reviewing options, “including potential appeal to US Supreme Court.”

It’s been almost four years since the FDA approved Erelzi, Sandoz’s copycat version of Enbrel. While sales of the Pfizer-partnered drug in the US — the market Amgen is in charge of — have dipped slightly during that time, it remains a solid megablockbuster with 2019 revenue slightly above $5 billion.